-
| CurrencyCode | USD |
|---|---|
| ISIN | None |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| Market Cap | 13M |
|---|---|
| PE Ratio | None |
| Target Price | 7 |
| Beta | -0.9 |
| Dividend Yield | None |
SeaStar Medical Holding Corporation, a commercial-stage medical technology company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation, and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI, and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for ICU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025